Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF TANEZUMAB IN ADULT PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY

NCT01087203 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01087203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01087203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF TANEZUMAB IN ADULT PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
March 30, 2010
Completion date
July 6, 2011
Enrollment
73 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathy